These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
102 related items for PubMed ID: 28134629
1. Liguzinediol Enhances the Inotropic Effect of Rat Hearts via Inhibition of Protein Phosphatase (PP1 and PP2A) Activities. Li S, Huang H, Zhang M, Wang W, Xue S, Gao Y, Xie M, Chen K, Liu F, Chen L. J Cardiovasc Pharmacol; 2017 Apr; 69(4):236-244. PubMed ID: 28134629 [Abstract] [Full Text] [Related]
2. The novel compound liguzinediol exerts positive inotropic effects in isolated rat heart via sarcoplasmic reticulum Ca2+ ATPase-dependent mechanism. Chen L, Xu Y, Li W, Wu H, Luo Z, Li X, Huang F, Young C, Liu Z, Zhou S. Life Sci; 2012 Oct 05; 91(11-12):402-408. PubMed ID: 22906633 [Abstract] [Full Text] [Related]
3. Scaffold evaluation of liguzinediol analogs as novel cardiotonic agents. Liu Z, Li W, Qin K, Wen K, Zhu CJ, Li NG, Bian HM, Wen HM, Chen L. Pharmazie; 2013 Dec 05; 68(12):926-32. PubMed ID: 24400437 [Abstract] [Full Text] [Related]
4. Decoy peptides targeted to protein phosphatase 1 inhibit dephosphorylation of phospholamban in cardiomyocytes. Oh JG, Kim J, Jang SP, Nguen M, Yang DK, Jeong D, Park ZY, Park SG, Hajjar RJ, Park WJ. J Mol Cell Cardiol; 2013 Mar 05; 56():63-71. PubMed ID: 23262438 [Abstract] [Full Text] [Related]
5. Prolactin-releasing peptide regulates cardiac contractility. Kónyi A, Skoumal R, Kubin AM, Füredi G, Perjés A, Farkasfalvi K, Sárszegi Z, Horkay F, Horváth IG, Tóth M, Ruskoaho H, Szokodi I. Regul Pept; 2010 Jan 08; 159(1-3):9-13. PubMed ID: 19616582 [Abstract] [Full Text] [Related]
6. Bay 60-7550, a PDE2 inhibitor, exerts positive inotropic effect of rat heart by increasing PKA-mediated phosphorylation of phospholamban. Wang YW, Gao QW, Xiao YJ, Zhu XJ, Gao L, Zhang WH, Wang RR, Chen KS, Liu FM, Huang HL, Chen L. Eur J Pharmacol; 2021 Jun 15; 901():174077. PubMed ID: 33798601 [Abstract] [Full Text] [Related]
7. p38α regulates SERCA2a function. Kaikkonen L, Magga J, Ronkainen VP, Koivisto E, Perjes Á, Chuprun JK, Vinge LE, Kilpiö T, Aro J, Ulvila J, Alakoski T, Bibb JA, Szokodi I, Koch WJ, Ruskoaho H, Kerkelä R. J Mol Cell Cardiol; 2014 Feb 15; 67():86-93. PubMed ID: 24361238 [Abstract] [Full Text] [Related]
8. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors. Swingle MR, Amable L, Lawhorn BG, Buck SB, Burke CP, Ratti P, Fischer KL, Boger DL, Honkanen RE. J Pharmacol Exp Ther; 2009 Oct 15; 331(1):45-53. PubMed ID: 19592665 [Abstract] [Full Text] [Related]
9. [Positive inotropic effect of atractylodin in normal rats and its underlying mechanism]. Gao L, Zhang WH, Wang YW, Zhu XJ, Xiao YJ, Gao QW, Li W, Chen L. Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2020 Sep 15; 36(5):408-413. PubMed ID: 33629552 [Abstract] [Full Text] [Related]
10. Echinochrome A regulates phosphorylation of phospholamban Ser16 and Thr17 suppressing cardiac SERCA2A Ca²⁺ reuptake. Kim HK, Youm JB, Jeong SH, Lee SR, Song IS, Ko TH, Pronto JR, Ko KS, Rhee BD, Kim N, Nilius B, Mischchenko NP, Fedoreyev SA, Stonik VA, Han J. Pflugers Arch; 2015 Oct 15; 467(10):2151-63. PubMed ID: 25410495 [Abstract] [Full Text] [Related]
11. Ischemia induces phospholamban dephosphorylation via activation of calcineurin, PKC-α, and protein phosphatase 1, thereby inducing calcium overload in reperfusion. Shintani-Ishida K, Yoshida K. Biochim Biophys Acta; 2011 Jul 15; 1812(7):743-51. PubMed ID: 21447388 [Abstract] [Full Text] [Related]
14. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. Cirak Y, Varol U, Atmaca H, Kisim A, Sezgin C, Karabulut B, Uzunoglu S, Uslu R, Karaca B. BJU Int; 2012 Dec 15; 110(11 Pt C):E1147-54. PubMed ID: 22882676 [Abstract] [Full Text] [Related]
15. Synthesis and positive inotropic activity evaluation of liguzinediol metabolites. Zhu HH, Chen YQ, Cheng D, Li W, Wang TL, Wen HM, Chen L, Liu J. Bioorg Med Chem Lett; 2016 Feb 01; 26(3):882-884. PubMed ID: 26725025 [Abstract] [Full Text] [Related]
17. Liguzinediol improved the heart function and inhibited myocardial cell apoptosis in rats with heart failure. Li Y, Song P, Zhu Q, Yin QY, Ji JW, Li W, Bian HM. Acta Pharmacol Sin; 2014 Oct 01; 35(10):1257-64. PubMed ID: 25220638 [Abstract] [Full Text] [Related]
18. Synthesis and biological evaluation of liguzinediol mono- and dual ester prodrugs as promising inotropic agents. Zhang J, Li W, Wen HM, Zhu HH, Wang TL, Cheng D, Yang KD, Chen YQ. Molecules; 2014 Nov 05; 19(11):18057-72. PubMed ID: 25379643 [Abstract] [Full Text] [Related]
19. Early cardiac dysfunction is rescued by upregulation of SERCA2a pump activity in a rat model of metabolic syndrome. Miklós Z, Kemecsei P, Bíró T, Marincsák R, Tóth BI, Op den Buijs J, Benis É, Drozgyik A, Ivanics T. Acta Physiol (Oxf); 2012 Jul 05; 205(3):381-93. PubMed ID: 22289164 [Abstract] [Full Text] [Related]
20. Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat. Matus M, Kucerova D, Kruzliak P, Adameova A, Doka G, Turcekova K, Kmecova J, Kyselovic J, Krenek P, Kirchhefer U, Mueller FU, Boknik P, Klimas J. Mol Cell Biochem; 2015 May 05; 403(1-2):199-208. PubMed ID: 25663023 [Abstract] [Full Text] [Related] Page: [Next] [New Search]